Global Neuroprotective Drugs Market Research Report 2021
Table of Contents1 Neuroprotective Drugs Market Overview
1.1 Product Overview and Scope of Neuroprotective Drugs
1.2 Neuroprotective Drugs Segment by Type
1.2.1 Global Neuroprotective Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Cholinesterase inhibitors
1.2.3 Anti-inflammatory
1.2.4 Others
1.3 Neuroprotective Drugs Segment by Application
1.3.1 Neuroprotective Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Alzheimer's disease
1.3.3 Parkinson's disease
1.3.4 Others
1.4 Global Neuroprotective Drugs Market Size Estimates and Forecasts
1.4.1 Global Neuroprotective Drugs Revenue 2016-2027
1.4.2 Global Neuroprotective Drugs Sales 2016-2027
1.4.3 Neuroprotective Drugs Market Size by Region: 2016 Versus 2021 Versus 2027
2 Neuroprotective Drugs Market Competition by Manufacturers
2.1 Global Neuroprotective Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Neuroprotective Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Neuroprotective Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Neuroprotective Drugs Manufacturing Sites, Area Served, Product Type
2.5 Neuroprotective Drugs Market Competitive Situation and Trends
2.5.1 Neuroprotective Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Neuroprotective Drugs Players Market Share by Revenue
2.5.3 Global Neuroprotective Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neuroprotective Drugs Retrospective Market Scenario by Region
3.1 Global Neuroprotective Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Neuroprotective Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Neuroprotective Drugs Market Facts & Figures by Country
3.3.1 North America Neuroprotective Drugs Sales by Country
3.3.2 North America Neuroprotective Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Neuroprotective Drugs Market Facts & Figures by Country
3.4.1 Europe Neuroprotective Drugs Sales by Country
3.4.2 Europe Neuroprotective Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Neuroprotective Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Neuroprotective Drugs Sales by Region
3.5.2 Asia Pacific Neuroprotective Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Neuroprotective Drugs Market Facts & Figures by Country
3.6.1 Latin America Neuroprotective Drugs Sales by Country
3.6.2 Latin America Neuroprotective Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Neuroprotective Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Neuroprotective Drugs Sales by Country
3.7.2 Middle East and Africa Neuroprotective Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Neuroprotective Drugs Historic Market Analysis by Type
4.1 Global Neuroprotective Drugs Sales Market Share by Type (2016-2021)
4.2 Global Neuroprotective Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Neuroprotective Drugs Price by Type (2016-2021)
5 Global Neuroprotective Drugs Historic Market Analysis by Application
5.1 Global Neuroprotective Drugs Sales Market Share by Application (2016-2021)
5.2 Global Neuroprotective Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Neuroprotective Drugs Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Genervon
6.1.1 Genervon Corporation Information
6.1.2 Genervon Description and Business Overview
6.1.3 Genervon Neuroprotective Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Genervon Product Portfolio
6.1.5 Genervon Recent Developments/Updates
6.2 NeuroVive Pharmaceutical
6.2.1 NeuroVive Pharmaceutical Corporation Information
6.2.2 NeuroVive Pharmaceutical Description and Business Overview
6.2.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 NeuroVive Pharmaceutical Product Portfolio
6.2.5 NeuroVive Pharmaceutical Recent Developments/Updates
6.3 Ceregene
6.3.1 Ceregene Corporation Information
6.3.2 Ceregene Description and Business Overview
6.3.3 Ceregene Neuroprotective Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Ceregene Product Portfolio
6.3.5 Ceregene Recent Developments/Updates
6.4 BHR Pharma
6.4.1 BHR Pharma Corporation Information
6.4.2 BHR Pharma Description and Business Overview
6.4.3 BHR Pharma Neuroprotective Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 BHR Pharma Product Portfolio
6.4.5 BHR Pharma Recent Developments/Updates
6.5 Neuren Pharmaceuticals
6.5.1 Neuren Pharmaceuticals Corporation Information
6.5.2 Neuren Pharmaceuticals Description and Business Overview
6.5.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Neuren Pharmaceuticals Product Portfolio
6.5.5 Neuren Pharmaceuticals Recent Developments/Updates
6.6 Allon therapeutics
6.6.1 Allon therapeutics Corporation Information
6.6.2 Allon therapeutics Description and Business Overview
6.6.3 Allon therapeutics Neuroprotective Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Allon therapeutics Product Portfolio
6.6.5 Allon therapeutics Recent Developments/Updates
6.7 Bionure
6.6.1 Bionure Corporation Information
6.6.2 Bionure Description and Business Overview
6.6.3 Bionure Neuroprotective Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Bionure Product Portfolio
6.7.5 Bionure Recent Developments/Updates
7 Neuroprotective Drugs Manufacturing Cost Analysis
7.1 Neuroprotective Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Neuroprotective Drugs
7.4 Neuroprotective Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Neuroprotective Drugs Distributors List
8.3 Neuroprotective Drugs Customers
9 Neuroprotective Drugs Market Dynamics
9.1 Neuroprotective Drugs Industry Trends
9.2 Neuroprotective Drugs Growth Drivers
9.3 Neuroprotective Drugs Market Challenges
9.4 Neuroprotective Drugs Market Restraints
10 Global Market Forecast
10.1 Neuroprotective Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Neuroprotective Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Neuroprotective Drugs by Type (2022-2027)
10.2 Neuroprotective Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Neuroprotective Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Neuroprotective Drugs by Application (2022-2027)
10.3 Neuroprotective Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Neuroprotective Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Neuroprotective Drugs by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesTable 1. Global Neuroprotective Drugs Sales (MT) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Neuroprotective Drugs Sales (MT) Comparison by Application (2021-2027)
Table 3. Global Neuroprotective Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Neuroprotective Drugs Covered in This Study
Table 5. Global Neuroprotective Drugs Sales (MT) of Key Manufacturers (2016-2021)
Table 6. Global Neuroprotective Drugs Sales Share by Manufacturers (2016-2021)
Table 7. Global Neuroprotective Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Neuroprotective Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Neuroprotective Drugs Average Price (USD/Kg) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Neuroprotective Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Neuroprotective Drugs Product Type
Table 12. Global Neuroprotective Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Neuroprotective Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroprotective Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Neuroprotective Drugs Sales by Region (2016-2021) & (MT)
Table 16. Global Neuroprotective Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Neuroprotective Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Neuroprotective Drugs Sales by Country (2016-2021) & (MT)
Table 19. North America Neuroprotective Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Neuroprotective Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Neuroprotective Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Neuroprotective Drugs Sales by Country (2016-2021) & (MT)
Table 23. Europe Neuroprotective Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Neuroprotective Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Neuroprotective Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Neuroprotective Drugs Sales by Region (2016-2021) & (MT)
Table 27. Asia Pacific Neuroprotective Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Neuroprotective Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Neuroprotective Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Neuroprotective Drugs Sales by Country (2016-2021) & (MT)
Table 31. Latin America Neuroprotective Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Neuroprotective Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Neuroprotective Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Neuroprotective Drugs Sales by Country (2016-2021) & (MT)
Table 35. Middle East and Africa Neuroprotective Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Neuroprotective Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Neuroprotective Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Neuroprotective Drugs Sales (MT) by Type (2016-2021)
Table 39. Global Neuroprotective Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Neuroprotective Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Neuroprotective Drugs Revenue Share by Type (2016-2021)
Table 42. Global Neuroprotective Drugs Price (USD/Kg) by Type (2016-2021)
Table 43. Global Neuroprotective Drugs Sales (MT) by Application (2016-2021)
Table 44. Global Neuroprotective Drugs Sales Market Share by Application (2016-2021)
Table 45. Global Neuroprotective Drugs Revenue (Million US$) by Application (2016-2021)
Table 46. Global Neuroprotective Drugs Revenue Share by Application (2016-2021)
Table 47. Global Neuroprotective Drugs Price (USD/Kg) by Application (2016-2021)
Table 48. Genervon Corporation Information
Table 49. Genervon Description and Business Overview
Table 50. Genervon Neuroprotective Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 51. Genervon Neuroprotective Drugs Product
Table 52. Genervon Recent Developments/Updates
Table 53. NeuroVive Pharmaceutical Corporation Information
Table 54. NeuroVive Pharmaceutical Description and Business Overview
Table 55. NeuroVive Pharmaceutical Neuroprotective Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 56. NeuroVive Pharmaceutical Neuroprotective Drugs Product
Table 57. NeuroVive Pharmaceutical Recent Developments/Updates
Table 58. Ceregene Corporation Information
Table 59. Ceregene Description and Business Overview
Table 60. Ceregene Neuroprotective Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 61. Ceregene Neuroprotective Drugs Product
Table 62. Ceregene Recent Developments/Updates
Table 63. BHR Pharma Corporation Information
Table 64. BHR Pharma Description and Business Overview
Table 65. BHR Pharma Neuroprotective Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 66. BHR Pharma Neuroprotective Drugs Product
Table 67. BHR Pharma Recent Developments/Updates
Table 68. Neuren Pharmaceuticals Corporation Information
Table 69. Neuren Pharmaceuticals Description and Business Overview
Table 70. Neuren Pharmaceuticals Neuroprotective Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 71. Neuren Pharmaceuticals Neuroprotective Drugs Product
Table 72. Neuren Pharmaceuticals Recent Developments/Updates
Table 73. Allon therapeutics Corporation Information
Table 74. Allon therapeutics Description and Business Overview
Table 75. Allon therapeutics Neuroprotective Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 76. Allon therapeutics Neuroprotective Drugs Product
Table 77. Allon therapeutics Recent Developments/Updates
Table 78. Bionure Corporation Information
Table 79. Bionure Description and Business Overview
Table 80. Bionure Neuroprotective Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 81. Bionure Neuroprotective Drugs Product
Table 82. Bionure Recent Developments/Updates
Table 83. Production Base and Market Concentration Rate of Raw Material
Table 84. Key Suppliers of Raw Materials
Table 85. Neuroprotective Drugs Distributors List
Table 86. Neuroprotective Drugs Customers List
Table 87. Neuroprotective Drugs Market Trends
Table 88. Neuroprotective Drugs Growth Drivers
Table 89. Neuroprotective Drugs Market Restraints
Table 90. Global Neuroprotective Drugs Sales Forecast by Type (2022-2027) & (MT)
Table 91. Global Neuroprotective Drugs Sales Market Share Forecast by Type (2022-2027)
Table 92. Global Neuroprotective Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 93. Global Neuroprotective Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 94. Global Neuroprotective Drugs Sales Forecast by Application (2022-2027) & (MT)
Table 95. Global Neuroprotective Drugs Sales Market Share Forecast by Application (2022-2027)
Table 96. Global Neuroprotective Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 97. Global Neuroprotective Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 98. Global Neuroprotective Drugs Sales Forecast by Region (2022-2027) & (MT)
Table 99. Global Neuroprotective Drugs Sales Market Share Forecast by Region (2022-2027)
Table 100. Global Neuroprotective Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 101. Global Neuroprotective Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of FiguresFigure 1. Product Picture of Neuroprotective Drugs
Figure 2. Global Neuroprotective Drugs Market Share by Type in 2020 & 2027
Figure 3. Cholinesterase inhibitors Product Picture
Figure 4. Anti-inflammatory Product Picture
Figure 5. Others Product Picture
Figure 6. Global Neuroprotective Drugs Market Share by Application in 2020 & 2027
Figure 7. Alzheimer's disease
Figure 8. Parkinson's disease
Figure 9. Others
Figure 10. Global Neuroprotective Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Neuroprotective Drugs Market Size 2016-2027 (US$ Million)
Figure 12. Global Neuroprotective Drugs Sales 2016-2027 (MT)
Figure 13. Global Neuroprotective Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 14. Neuroprotective Drugs Sales Share by Manufacturers in 2020
Figure 15. Global Neuroprotective Drugs Revenue Share by Manufacturers in 2020
Figure 16. The Global 5 and 10 Largest Neuroprotective Drugs Players: Market Share by Revenue in 2020
Figure 17. Neuroprotective Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 18. Global Neuroprotective Drugs Sales Market Share by Region (2016-2021)
Figure 19. Global Neuroprotective Drugs Sales Market Share by Region in 2020
Figure 20. Global Neuroprotective Drugs Revenue Market Share by Region (2016-2021)
Figure 21. Global Neuroprotective Drugs Revenue Market Share by Region in 2020
Figure 22. U.S. Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Canada Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Germany Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. France Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. U.K. Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Italy Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Russia Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. China Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Japan Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. South Korea Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. India Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Australia Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Taiwan Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Indonesia Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Thailand Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Malaysia Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Philippines Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Vietnam Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Mexico Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Brazil Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Argentina Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Turkey Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Saudi Arabia Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. U.A.E Neuroprotective Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Sales Market Share of Neuroprotective Drugs by Type (2016-2021)
Figure 47. Sales Market Share of Neuroprotective Drugs by Application (2016-2021)
Figure 48. Sales Market Share of Neuroprotective Drugs by Application in 2020
Figure 49. Revenue Share of Neuroprotective Drugs by Application (2016-2021)
Figure 50. Revenue Share of Neuroprotective Drugs by Application in 2020
Figure 51. Manufacturing Cost Structure of Neuroprotective Drugs
Figure 52. Manufacturing Process Analysis of Neuroprotective Drugs
Figure 53. Neuroprotective Drugs Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed